



Contact:

Madhusudan V. Peshwa, PhD
Vice President Research and Development
MaxCyte, Inc.
(301) 944-1700

For Immediate Release

**MaxCyte To Be Featured Speaker at the Williamsburg BioProcessing Foundation
Viral Vectors & Vaccines 12th Annual Meeting**

Gaithersburg, MD, November 9, 2005 – MaxCyte, Inc., a clinical stage therapeutic company and pioneer in clinical scale, non-viral cell loading systems, announces Madhusudan V. Peshwa, Ph.D., Vice President Research and Development, will be speaking at the Williamsburg BioProcessing Foundation Viral Vectors & Vaccines 12th Annual Meeting in Austin, Texas, on Monday, November 14, 2005, at 3:30 PM. Dr. Peshwa’s presentation entitled “Overcoming the Enablement Challenge in the Development and Manufacture of Viral Vectors”, will discuss utilizing MaxCyte’s proprietary cell loading technologies in the development and scale-up of processes for enablement of viral vector manufacturing.

“Engineering cellular systems to consistently augment or affect specific biological function using safe, cGMP compliant, scalable technologies represents the key challenge in the development of cellular therapeutics and for biopharmaceutical production. Clinical development of novel viral vectors and vaccines has been significantly hindered by the inability of current processing technologies to obtain consistent titer, yield, and potency while employing cGMP compliant aseptic technologies that result in consistent and scalable processes,” said Dr. Peshwa. “MaxCyte’s clinical grade, non-viral cell loading and gene delivery systems offer high yield, robust, and scalable processes. MaxCyte has selectively licensed its technologies for clinical / commercial development and manufacture of cell and gene therapy products and continues to seek business opportunities in the manufacture of viral vectors and vaccines.”

About MaxCyte

MaxCyte, Inc. is a clinical stage company developing cell-based therapeutics primarily in the areas of oncology and regenerative medicine. MaxCyte’s pipeline includes one product in Phase I/II clinical trials for the treatment of Chronic Lymphocytic Leukemia (CLL) and several preclinical candidates to treat a variety of diseases with unmet needs. The company also offers its unparalleled, customizable flow based cell loading technology to partners who take advantage of its advanced capabilities for cell-based therapeutic development and biotherapeutic (viral vector) manufacturing through licensing relationships. Partners are currently working to develop therapeutics for pulmonary, cardiovascular and infectious disease, cancer and regenerative medicine.

For more information, visit <http://www.maxcyte.com>.

This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management’s current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.